Insights - It looks like a risk associated with some approved antibiotics may not be a concern for Cempra’s (CEMP) own late-stage candidate, solithromycin. Cempra announced on … Continue Reading
Read nowResearch - BioDelivery Sciences (BDSI) and partner Endo Health Solutions (ENDP) announced on the 23rd that the second of three phase 3 trials testing one of its lead drug candidates, BEMA buprenorphine, … Continue Reading
Read nowResearch - Update from Friday, January 31st at 9:45 AM ET Today the company revealed that it’s selling 5.76M shares at $21. What would have originally been … Continue Reading
PremiumResearch - With the JP Morgan Healthcare conference in the rearview, here are updates on a few names that PropThink suggested already this year, all of which … Continue Reading
PremiumResearch - Update after the bell, BioLife announces a 1:14 reverse split. Talk about timing. BioLife Solutions (BLFS) (which Mr. Deryugin wrote about this morning below and in advance … Continue Reading
Read nowResearch - Tekmira Pharmaceuticals (TKMR) continues to recast itself as a pipeline, product-focused company, steering away from investors’ long-time perception of the Canadian firm as a developer … Continue Reading
PremiumInsights - Neuralstem (CUR) announced a $19.65M registered direct offering on Friday morning. Recall that Jason Napodano of Zacks Small-Cap Research has covered Neuralstem at length for … Continue Reading
Read now
